Head to Head Survey: Propanc Biopharma (NASDAQ:PPCB) vs. Absci (NASDAQ:ABSI)

Absci (NASDAQ:ABSI) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations and dividends.

Insider and Institutional Ownership

52.0% of Absci shares are held by institutional investors. 10.5% of Absci shares are held by insiders. Comparatively, 28.5% of Propanc Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

Absci has a beta of 2.35, meaning that its stock price is 135% more volatile than the S&P 500. Comparatively, Propanc Biopharma has a beta of 3.52, meaning that its stock price is 252% more volatile than the S&P 500.

Profitability

This table compares Absci and Propanc Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Absci	-6,450.76%	-66.32%	-57.01%
Propanc Biopharma	N/A	-151.28%	-109.53%

Analyst Recommendations

This is a breakdown of recent ratings for Absci and Propanc Biopharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Absci	1	0	8	0	2.78
Propanc Biopharma	1	0	0	0	1.00

Absci currently has a consensus price target of $13.43, indicating a potential upside of 45.79%. Given Absci’s stronger consensus rating and higher possible upside, analysts plainly believe Absci is more favorable than Propanc Biopharma.

Valuation and Earnings

This table compares Absci and Propanc Biopharma”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Absci	$2.80 million	512.86	-$115.18 million	($0.83)	-11.10
Propanc Biopharma	N/A	N/A	-$58.92 million	($24.25)	-0.05

Propanc Biopharma has lower revenue, but higher earnings than Absci. Absci is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Absci beats Propanc Biopharma on 8 of the 13 factors compared between the two stocks.

About Absci

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

About Propanc Biopharma

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.